Top 50 Biotech Startup Investors in Australia (July 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Uniseed
VC Fund
|
27 | Australia, United States, United Kingdom | Series A, Seed, Series B | Biotechnology, Health Care, Manufacturing | $471k–$22M |
|
Uniseed Ventures
VC Fund
|
18 | Australia, United States, United Kingdom | Series A, Seed | Biotechnology, Health Care, Manufacturing | $381k–$16M |
|
Brandon Capital
VC Fund
|
17 | Australia, United Kingdom, United States | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $673k–$115M |
|
Main Sequence Ventures
VC Fund
|
11 | Australia, United States, Philippines | Seed, Series A, Series B | Software, Artificial Intelligence, Manufacturing | $1M–$73M |
|
Medical Research Commercialisation Fund (MRCF)
VC Fund
|
11 | Australia, United States, United Kingdom | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $1.3M–$16M |
|
Stoic VC
VC Fund
|
8 | Australia, United States, United Kingdom | Seed, Series A | Biotechnology, Medical, Health Care | $600k–$16M |
|
Artesian VC
VC Fund
|
7 | Australia, United States, Hong Kong | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, Health Care | $40k–$15M |
|
Melbourne Angels
VC Fund
|
6 | Australia, United States, New Zealand | Angel, Seed | Biotechnology, Information Technology, Energy | $34k–$1.3M |
|
Horizons Ventures
VC Fund
|
5 | United States, United Kingdom, Canada | Series A, Series B, Seed | Biotechnology, Software, Artificial Intelligence | $1M–$110M |
|
Sydney Angels
VC Fund
|
5 | Australia, United States | Seed, Angel, Pre-Seed | Software, SaaS, Health Care | $120k–$1.5M |
|
Breakthrough Victoria
VC Fund
|
4 | Australia, United States, Philippines | Seed, Series A, Venture - Series Unknown | Health Care, Manufacturing, Biotechnology | $600k–$30M |
|
Brisbane Angels
VC Fund
|
4 | Australia, United States, New Zealand | Seed, Pre-Seed, Angel | Software, Information Technology, Artificial Intelligence | $120k–$1.5M |
|
IP Group Australia
VC Fund
|
4 | Australia, New Zealand | Seed, Series A, Pre-Seed | Biotechnology, Manufacturing, Renewable Energy | $811k–$29M |
|
OneVentures
VC Fund
|
4 | Australia, United States, Israel | Series A, Debt Financing | Software, Health Care, Biotechnology | $1M–$20M |
|
Grok Ventures
VC Fund
|
3 | Australia, United States, Singapore | Series A, Seed, Series B | Renewable Energy, Software, Biotechnology | $808k–$150M |
|
Tin Alley Ventures
VC Fund
|
3 | Australia, Philippines | Pre-Seed, Seed, Series B | Biotechnology, Medical, Software | $430k–$2.9M |
|
Yuuwa Capital
VC Fund
|
3 | Australia | Series A, Seed, Series B | Biotechnology, Software, Analytics | $131k–$6.4M |
|
GBS Ventures
VC Fund
|
3 | United States, Australia, United Kingdom | Series A, Series B | Biotechnology, Health Care, Medical Device | $2.2M–$35M |
|
Australian Medical Angels
VC Fund
|
3 | Australia, Hong Kong, Singapore | Seed, Pre-Seed, Series A | Health Care, Medical, Software | $7k–$3.5M |
|
Possible Ventures
VC Fund
|
3 | Germany, Australia, United States | Seed, Pre-Seed, Series A | Software, Biotechnology, Information Technology | $549k–$47M |
|
Starfish Ventures
VC Fund
|
3 | Australia, United States, Philippines | Series A, Series B | Software, Enterprise Software, Internet | $2M–$18M |
|
QIC BioVentures
VC Fund
|
3 | Australia | Series A | Medical, Health Care, Biotechnology | |
|
Clean Energy Finance Corporation
VC Fund
|
3 | Australia, United States, United Kingdom | Debt Financing, Series B, Post-IPO Debt | Energy, Renewable Energy, Real Estate | $5M–$719M |
|
Investible
VC Fund
|
2 | Australia, United States, Singapore | Seed, Series A, Pre-Seed | Software, Information Technology, FinTech | $250k–$20M |
|
UniQuest
VC Fund
|
2 | Australia, United Kingdom | Seed, Series A, Series B | Biotechnology, Water, Medical | |
|
Empath Ventures
VC Fund
|
2 | United States, United Kingdom, Canada | Seed, Pre-Seed, Convertible Note | Health Care, Biotechnology, Personal Health | $1.5M–$12M |
|
The George Institute for Global Health
VC Fund
|
2 | Australia | Seed | Biometrics, Health Care, Biotechnology | |
|
Lowercarbon Capital
VC Fund
|
2 | United States, United Kingdom, France | Seed, Series A, Series B | Renewable Energy, Energy, Biotechnology | $3.7M–$150M |
|
Global Health Investment Fund (GHIF)
VC Fund
|
2 | United States, India, Austria | Series B, Series C | Health Care, Biotechnology, Medical Device | $4.5M–$18M |
|
Vectr
VC Fund
|
2 | United States, Hong Kong, Singapore | Seed, Series A, Series B | FinTech, Financial Services, Artificial Intelligence | $547k–$70M |
|
Folklore Ventures
VC Fund
|
2 | Australia, United States, New Zealand | Seed, Series A | Software, Information Technology, Apps | $500k–$21M |
|
Hitachi Ventures
VC Fund
|
2 | United States, Australia, United Kingdom | Series A, Series B, Series C | Software, Artificial Intelligence, Information Technology | $10M–$200M |
|
BridgeLane Capital
VC Fund
|
2 | Australia, Germany, United States | Seed, Series A | Software, Real Estate, Financial Services | $673k–$6.1M |
|
Closed Loop Partners
VC Fund
|
2 | United States, United Kingdom, Canada | Seed, Series A, Debt Financing | Recycling, Manufacturing, Artificial Intelligence | $2M–$16M |
|
Hostplus
VC Fund
|
2 | Australia, United Kingdom, United States | Series A, Series B, Series C | Software, Biotechnology, Semiconductor | $6.3M–$111M |
|
Intermediate Capital Group
VC Fund
|
2 | United Kingdom, France, United States | Private Equity, Series B | Biotechnology, Health Care, Therapeutics | $49M–$439M |
|
Canaan Partners
VC Fund
|
2 | United States, United Kingdom, Israel | Series A, Series B, Series C | Software, Biotechnology, Health Care | $5M–$75M |
|
Catalio Capital Management
VC Fund
|
2 | United States, Switzerland, Israel | Series A, Series B | Biotechnology, Health Care, Life Science | $15M–$150M |
|
M8 Ventures
VC Fund
|
2 | Australia, United States | Pre-Seed, Seed, Series A | Health Care, SaaS, Medical | $200k–$8M |
|
Tenacious Ventures
VC Fund
|
2 | Australia, United States | Seed, Pre-Seed, Series A | Agriculture, AgTech, Farming | $896k–$49M |
|
Radar Ventures
VC Fund
|
2 | Australia, United States, Hong Kong | Seed, Pre-Seed, Series A | Health Care, Biotechnology, Artificial Intelligence | $1.9M–$12M |
|
Renew Pharmaceuticals
VC Fund
|
2 | Australia | Series A, Series B | Health Care, Biotechnology, Medical Device | $5.6M–$6M |
|
SOSV
VC Fund
|
2 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
South Australian Venture Capital Fund
VC Fund
|
2 | Australia | Seed, Series B, Series A | Health Care, Biotechnology, Internet of Things | $1M–$24M |
|
Queensland Investment Corporation
VC Fund
|
2 | Australia, United States | Seed, Series A | Information Technology, Software, Renewable Energy | $673k–$10M |
|
Monash University
VC Fund
|
2 | Australia | Series A, Seed | Biopharma, Therapeutics, Biotechnology | $17M–$19M |
|
Mike Wallas
Angel
|
2 | Australia | Seed | Video, Water, Biotechnology | |
|
IP Group
VC Fund
|
2 | United Kingdom, United States, Australia | Seed, Series A | Health Care, Biotechnology, Therapeutics | $393k–$23M |
|
Time Ventures
VC Fund
|
2 | United States, Canada, Germany | Series A, Series B, Seed | Software, Information Technology, Artificial Intelligence | $2.9M–$450M |
|
Allan Moss
Angel
|
2 | Australia, United States, The Netherlands | Series A, Seed | Health Care, Medical Device, Biotechnology | $2.4M–$8.8M |
| Access all 317 investors in Australia Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 86
- Round size: Seed $600k–$3.5M; Series A $1.6M–$16M; Series B $471k–$22M
- Lead/follow: 22% lead, 78% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- DeteQt — Semiconductor chip-based quantum magnetic field sensors using diamond - navigation, mining, medical imaging
- Plasmaleap —
- Analog Quantum Circuits — Analog Quantum Circuits develops analog components for solid-state quantum computers.
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Seed
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 57
- Round size: Seed $381k–$4.2M; Series A $1.3M–$16M
- Lead/follow: 12% lead, 88% follow
- Last fund: May invest from a new fund soon — raised $14M in 2017
Portfolio highlights
- BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Morse Micro — Morse Micro is a fast-growing wireless integrated circuit solutions company that is reinventing Wi-Fi for the Internet of Things (IoT). The company was founded by Wi-Fi pioneers and innovators, Michael De Nil and Andrew Terry, joined by the original Wi-Fi inventor Prof. Neil Weste and wireless industry veterans, whose teams designed Wi-Fi chipsinto billions of smartphones. Headquartered in Australia with offices in China and the U.S., Morse Micro’s strong and diverse system team, portfolio of IP and patents, enables Wi-Fi HaLow connectivity across the complete IoT ecosystem, from surveillance systems and access control to industrial automation and mobile devices, allowing connected devices to reach farther. www.morsemicro.com
Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Australia, United Kingdom, United States
Investor stats
- Total investments: 69
- Round size: Seed $673k–$6.7M; Series A $4.9M–$115M; Series B $6.4M–$68M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $210M in 2019
Portfolio highlights
- Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.
- OncoRes Medical — OncoRes Medical develops an imaging technology to provide intraoperative information available to surgeons to assist with the identification of tumor and healthy tissue.OncoRes Medical is an early-stage medical device company located in Perth, Western Australia and is developing the patent-protected technology in collaboration with leadingresearchers at the University of Western Australia and the Harry Perkins Institute of Medical Research and breast cancer surgeons at the Western Australian public health system.With funding provided by the Medical Research Commercialisation Fund (MRCF), OncoRes Medical aims to develop the technology for use in clinical applications that require the real-time assessment of tissue microstructure.
- NRG Therapeutics — energizing drug discovery in neurodegenerative diseases.
We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Manufacturing
- Stage:Seed, Series A, Series B
- Geography: Australia, United States, Philippines
Investor stats
- Total investments: 127
- Round size: Seed $1M–$7M; Series A $4.5M–$29M; Series B $13M–$73M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $303M in 2023
Portfolio highlights
- Swoop Aero — Transforming how the world moves by making access to the skies seamless. Kite Aero is the only end-to-end drone logistics platform on the planet. We unlock the potential of the sky, for the good of us all. Currently we serve over 4.5 million people in 6 continents. By 2030, our reach will extend to 1 billion.
- Loam Bio — Loam has designed farmer-focused carbon projects that support farmers to build stable soil carbon in cropping and mixed farming systems.
- Castlepoint Systems — Startux X is the perfect multi-purpose Startup Webflow Template. Get it today and design a state-of-the-art website for your technology startup or company in record time.
Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 26
- Round size: Series A $1.3M–$13M; Series B $6.4M–$16M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- MycRx — MecRx is a drug development company that works on new treatments for cancer and novel mechanism of action antibiotics. Using proprietary “hit identification” technology, MecRx is developing inhibitors of cMyc, a protein that is deregulated in over 50% of all human cancers. MecRx draws on the expertise of the Peter MacCallum Cancer Centre and CSIROand is headquartered in Melbourne, Australia.MecRx was founded in 2013 by an ex-pharma/biotech team. MecRx is run as a virtual company based in Melbourne, Australia and its shareholders and service providers include the Peter MacCallum Cancer Institute and CSIRO. The company secured $5m Series A investment from the MRCF (www.mrcf.com.au) and CSIRO in 2015.
- Currus Biologics — Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
- Azura Ophthalmics — Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
Stoic VC is an early-stage venture fund backing founders at the forefront of University Innovation. We partner with Uniseed to accelerate the commercialisation of university research across the ANZ.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Series A
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 24
- Round size: Seed $600k–$4.2M; Series A $7.6M–$16M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Ena Respiratory — Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs.
- Lenexa Medical — Lenexa Medical is an Australian based MedTech company.
- Kinoxis Therapeutics — Developing novel therapeutics for social dysfunction and substance use disorders.
Artesian Capital Management is an alternative investments management company, which was spun out of ANZ Banking Group's capital markets business in 2004, with backing from ANZ Private Equity. Artesian's founding partners, purchased ANZ's stake in 2005. The company has subsequently been fully owned by partners and staff. Since 2004,Artesian has managed specialised funds focused on credit arbitrage and relative-value strategies across global financial markets. In 2008, while continuing to manage credit relative value investment strategies from its New York, London and Singapore offices, Artesian began to make principal investments in seed/early-stage ventures from its offices in Sydney, Melbourne and Shanghai. In 2011, Artesian launched the first of its early stage venture capital funds and now manages AUD +255m. Artesian's VC strategy is to partner with best of breed accelerators, incubators, angel groups and university programs. In 2017, Artesian launched its China VC Fund with a USD 50m cornerstone investment industry super fund Hostplus. Artesian will soon launch a Southeast Asia VC Fund.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Pre-Seed
- Geography: Australia, United States, Hong Kong
Investor stats
- Total investments: 246
- Round size: Seed $135k–$4.6M; Pre-Seed $40k–$1.5M; Series A $2.3M–$15M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Vaulta — Discover Vaulta's high-performance batteries for sustainable energy solutions. Revolutionising power with easy installation, maintenance, and recycling. Join the Australian-made energy revolution today!
- Andromeda Robotics — At Andromeda, our personalised robot companions are helping Australian aged care teams bring joy and connection to residents to improve wellbeing.
- Infiction labs — SPARC 1.2 is a solar panel robotic cleaning system designed and developed by Infiction Labs Pvt Ltd for commercial solar plants.
Melbourne Angels was formed in Melbourne, Australia in early 2007. Melbourne Angels is the leading group of private investors in Victoria who actively invest in early stage and growth technology companies.The group has a strong and experienced core of members that generate deal flow, are experienced in evaluation of business propositions and actas mentors for the other members and the entrepreneurs. The members vary in age, gender, ethnicity, profession and type of experience. All members have experience of success at being entrepreneurial.This award winning group is consistently one of the most active startup investors in the country.
Show more...Investment focus
- Industry: Biotechnology, Information Technology, Energy
- Stage:Angel, Seed
- Geography: Australia, United States, New Zealand
Investor stats
- Total investments: 45
- Round size: Seed $34k–$1.3M; Angel $219k–$918k
- Lead/follow: 49% lead, 51% follow
Portfolio highlights
- Emanda — Emanda App helps business advisory firms and companies determine business value, auto-generate data rooms, set goals, and track progress daily via AI-driven tools.
- Auric Essentials — Auric - The Power of Scent. Revolutionise your well-being with Auric. Discover our state-of-the-art AI-powered AromaSphere diffuser and app, designed to personalise your aromatherapy experience.
- Bitwise Agronomy — Bitwise Agronomy uses AI to analyze crop video footage and provide growers with insights into crop health, growth, and yield potential.
Investing in the deep science and technology that can propel humanity towards a radically better future.
Show more...Investment focus
- Industry: Biotechnology, Software, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 255
- Round size: Seed $1M–$11M; Series A $6.2M–$50M; Series B $8M–$110M
- Lead/follow: 43% lead, 57% follow
Portfolio highlights
- Scopely — Scopely is an interactive entertainment and video game company, home to many top-grossing, award-winning franchises including “Star Trek™ Fleet Command,” “MARVEL Strike Force,” “Stumble Guys”, and “Yahtzee With Buddies,” among others.Scopely creates, publishes, and live-operates immersive games that empower a directed-by-consumer™ experience.Scopely is fueled by a world-class team and a proprietary technology platform Playgami™ that supports one of the diversified portfolios in the mobile games industry. Recognized multiple times as Company’s “World’s Most Innovative Companies,” Scopely is a multi-billion-dollar business due to its ability to create long-lasting game experiences that players enjoy for years. Scopely has operations in more than a dozen markets across Asia-Pacific, including Bangalore and Shanghai, among others; EMEA, including Barcelona and Dublin, among others; and North America, including Boulder, Colorado, and Culver City, California, among others, with additional game studio partners across four continents.
- Amper Music — Amper is an AI music composition company that develops tools for content creators of all kinds. Learn about our new enterprise platform, Score, as well as our creator API.
- Misfit Wearables — Misfit is focused on developing great wearable products: things that people would want to wear all the time for a long time. A pioneer in the emerging world of wearable sensor technology, the company is making products and services in the consumer health and fitness space to inspire people to be more active and develop healthy habits. Misfit’sfirst product is the Shine, an elegant personal activity tracker that can instantly sync with a smartphone just by placing the device on the screen. Misfit was founded in 2011 and headquartered in Burlingame, California.
Sydney Angels is a not-for-profit angel investment membership organisation. Since our establishment in 2008, they have stayed true to our mission of supporting the early-stage ecosystem by running processes and events that connect our investing members with promising early-stage companiesThey believe that encouraging smart investment in startupcompanies will benefit both our members’ portfolios and Australia’s emergent innovation economy.They see this as the ultimate win-win situation. Sydney Angels is led by an elected committee of ten volunteers who meet weekly. It is supported by an operations manager and alliance partners.
Show more...Investment focus
- Industry: Software, SaaS, Health Care
- Stage:Seed, Angel, Pre-Seed
- Geography: Australia, United States
Investor stats
- Total investments: 95
- Round size: Seed $120k–$1.3M; Angel $130k–$890k; Pre-Seed $337k–$1.5M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- Keeyu — keeyu. is a B2B SaaS platform that continuously monitors e-commerce transactions from payment to delivery. Should any issue emerge, our system immediately notifies the customer service team, enabling proactive issue resolution before it impacts the customer, saving them from opening a support ticket. The result is an enhanced post-purchaseexperience, ensuring sales retention and reducing customer complaints.Founded in 2023, the company is headquartered in Sydney, Australia, and is dedicated to empowering businesses to deliver exceptional post-purchase experiences.
- ExtrasJar — Swap health insurance premiums for balanced investments and get access to your funds when using health services.
- Mary Technology — Generate detailed chronologies from documents in minutes with Mary Technology. Achieve 90%+ time reduction and ensure 99%+ accuracy. Try for free.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!The Breakthrough Victoria Fund is a $2 billion investment by the Victorian Government to drive investment in research and innovation.
Show more...Investment focus
- Industry: Health Care, Manufacturing, Biotechnology
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Australia, United States, Philippines
Investor stats
- Total investments: 52
- Round size: Seed $708k–$6.8M; Series A $1.7M–$30M; Venture - Series Unknown $600k–$30M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- DeepDerm — DeepDerm is developing AI-enabled cameras that detect skin cancer without the need for painful biopsies.
- AlleSense — AlleSense develops a label-free optical imaging technology designed to enhance disease diagnosis by manipulating light-tissue interactions at the nanoscale. It's Mission is to Reimagining the standard microscope slide to make digital pathology faster, more accurate, and accessible without complex chemical staining.
- Deftbiotech — Deftbiotech is a biotech startup developing peptide-based antifungal treatments for nail and skin infections.
Formed in late 2006, the Brisbane Angels Pty Ltd is a large group of private investors who actively invest in early stage technology companies, usually in South East Queensland, Australia. The members are typically active or semi-retired former senior business executives, who apart from financial input can provide much needed value adding toinvestee companies through hands-on management experience and high level business networks.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Pre-Seed, Angel
- Geography: Australia, United States, New Zealand
Investor stats
- Total investments: 63
- Round size: Seed $120k–$1.5M; Angel $337k–$629k; Pre-Seed $200k–$1.4M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Giftbee — Giftbee is a B2B gifting marketplace with smart, eco-friendly solutions that enhance value and experience.
- Indi — indi is an assistant for your child's care journey; supporting advocacy, mental health & uniting the village of care.
- Ovum — Meet Ovum, the intelligent health journal mobile app designed for womankind.
Ip Group Australia build and support outstanding intellectual property-based companies.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Renewable Energy
- Stage:Seed, Series A, Pre-Seed
- Geography: Australia, New Zealand
Investor stats
- Total investments: 15
- Round size: Seed $1.3M–$2.3M; Pre-Seed $811k–$896k; Series A $3M–$29M
- Lead/follow: 47% lead, 53% follow
Portfolio highlights
- MGA Thermal — MGA Thermal, specialists in thermal energy storage technology. Renewable, high-power, economical, modular, safe and sustainable thermal storage solutions.
- Additive Assurance — Additive Assurance offers quality assurance for metal additive manufacturing.
- Jetra Therapeutics — Jetra Therapeutics develops new treatment for obesity-related liver disease designed to reduce stress in liver cells.
OneVentures is a later-stage venture capital firm focused on scaling Technology and Healthcare companies through growth equity and credit. The firm's role extends far beyond investment, as the firm actively guides companies toward achieving their next critical milestones. By leveraging decades of global experience and operational expertise,OneVentures accelerates growth and helps shape the future of its portfolio companies.A global growth focus drives their investment selection, with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Debt Financing
- Geography: Australia, United States, Israel
Investor stats
- Total investments: 80
- Round size: Series A $1.5M–$20M; Debt Financing $1M–$6.7M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $145M in 2022
Portfolio highlights
- me&u — me&u is an online ordering and payment application designed to order meals. They provide communication technology to order and pay through mobile phones at restaurants. Their process of ordering with waiters and splitting bills that enable users to order their food and pay bills through a digital payment platform.
- Truescope — Make better informed communications decisions with Truescope. Harnessing millions of media posts every day to deliver you real-time information that influences your business strategy.
- Vertero — Axial Therapeutics is a biotechnology company fundamentally changing the treatment of neurological diseases and disorders by harnessing groundbreaking science in the microbiome-gut-brain axis.
Backing a better tomorrow
Show more...Investment focus
- Industry: Renewable Energy, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, Singapore
Investor stats
- Total investments: 67
- Round size: Seed $808k–$10M; Series A $3.3M–$63M; Series B $12M–$150M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Endolith — Endolith is a biotech company transforming sustainable mining by leveraging microbes, synthetic biology, and cloud computing to extract more critical minerals like copper from low-grade ores. Working with the many of the leading mining companies, Endolith is advancing its innovative technology to commercial scale. Recognized as a finalist in theBHP Unearthed BioMetals cohort and a member of the Alaska Critical Minerals Collaborative, Endolith is driving the future of mining with sustainable, efficient, and responsible solutions for the clean energy transition.
- MAKO — Solving human problems with nature’s surfaces.
- Asterix Foods — Asterix Foods is a biotechnology company designed to build protein production using plant-cell culture techniques. The company's platform is developing and growing bioactive proteins for food that are scalable, functional, and complex, enabling users with plant cell-cultured and animal-free proteins.It was founded in 2022 and is located inTel Aviv, Israel.
Tin Alley Ventures collaborates with companies and researchers in the University of Melbourne's ecosystem to invest in & support world-changing businesses.
Show more...Investment focus
- Industry: Biotechnology, Medical, Software
- Stage:Pre-Seed, Seed, Series B
- Geography: Australia, Philippines
Investor stats
- Total investments: 7
- Round size: Pre-Seed $430k–$2.9M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- i14 — We are i14 — we sit at the intersection of Computational Cognitive Science and AI research, and have developed a new class of models called Laplace Sequence Models that are an order of magnitude faster and more efficient and multiples more accurate than the transformer. We’ve also built a foundation model platform that allows organisations tocreate private, domain-specific expert models deployable across any environment (on-prem, at the edge, on device, in a private cloud, or hosted by i14). Our research lab continues to push beyond many of the limitations of current AI, and has a host of research projects which are continually integrated to update our foundation model platform. We recently closed a $4M initial round and are preparing for the next round.
- Mirugen — Mirugen is a preclinical biotechnology company identifying the optimal set of cellular instructions to ask one cell type to become another.
- Kronus — Full-stack development infrastructure for safety-critical systems.
Yuuwa Capital is a $40M early-stage venture capital firm based in Perth, Western Australia. They are actively seeking outstanding investment opportunities where Yuuwa can provide both capital and expertise to help founders, management and early investors to turn good ideas into great companies.
Show more...Investment focus
- Industry: Biotechnology, Software, Analytics
- Stage:Series A, Seed, Series B
- Geography: Australia
Investor stats
- Total investments: 16
- Round size: Seed $131k–$808k; Series A $979k–$4.2M; Series B $2.6M–$6.4M
- Lead/follow: 63% lead, 37% follow
Portfolio highlights
- Nexgen Plants — Healthy plants, healthy people, living planet. Nexgen develop's plants for future generations that will improve the environment and health of future generations.
- Icetana — icetana Motion Intelligence dramatically improves the active monitoring of security surveillance networks, with AI video anomaly detection and video analytics.
- Agworld — Agworld Farm Management software allows you to collect data at all levels and enables you to extract maximum value from this data; optimising profitability. The Agworld ecosystem is utilised by growers, agronomists and service providers on farms across the world.
Founded in 1996, GBS invests in young businesses developing and commercialising products which, when combined with the right management and finance, will make a significant difference to patients' lives and deliver financial returns for their investors. Their areas of particular interest and expertise include human healthcare, biotechnologyproduct development and life science start-ups. In particular, recent investments have included biological or small molecule therapeutics, medical devices and diagnostics.GBS invests in private or public companies whether at start-up or later stages of company development. Their investors include major Australian superannuation funds.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical Device
- Stage:Series A, Series B
- Geography: United States, Australia, United Kingdom
Investor stats
- Total investments: 41
- Round size: Series A $2.2M–$9M; Series B $8.8M–$35M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Ivantis — Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development forthe treatment of other debilitating diseases within ophthalmology.
- Moximed — Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis.
- Elastagen — Elastagen is a clinical stage medical company with an advanced pipeline of products based on the human protein tropoelastin, a pioneering medical biomaterial. Elastin is a critical component of tissues in the human body which require the ability to stretch and recoil, such as the skin, lungs, arteries, elastic ligaments. Elastagen hasdeveloped a synthetic version of the elastin protein which is identical to that naturally present in the human body. Elastagen’s platform technology has potential applications in a number of areas including skin rejuvenation, scar remodelling and tissue repair. Elastagen was founded following the acquisition of intellectual property rights to the elastin technology which was developed by Prof Weiss at the University of Sydney. The Company has since successfully attracted capital from a number of leading Australian and overseas life science venture capital groups. Elastagen’s operations have expanded from its Australian base to include production in Europe and clinical operations in the UK.
Medical Angels is the premier medical and health-specific angel investment syndicate, comprised of over 1,000 clinicians from across Australia.
Show more...Investment focus
- Industry: Health Care, Medical, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: Australia, Hong Kong, Singapore
Investor stats
- Total investments: 16
- Round size: Seed $7k–$1.7M; Series A $3.3M–$3.5M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- GXE — At GXE, our mission is to build the all-in-one platform for unlisted assets and funds management. We provide investors, fund managers, and family offices with the tools they need to succeed and enable them to focus on their portfolios and investors whilst GXE takes care of everything else. A licensed financial services company, GXE holdsAustralian Financial Services Licence 460870 issued by the Australian Securities and Investments Commission. GXE welcomes clients across sectors including corporate, family offices, pension and superannuation fund managers, private equity, property, and venture capital.
- Graphics et al. — Graphics et al. is a software that offers to create graphic designs. Graphics et al. mission is to make scientific communication easier.
- Clean Slate Clinic — Clean Slate Clinic is a telehealth company that provides alcohol detox program who are struggling with alcohol.
Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, Australia, United States
Investor stats
- Total investments: 164
- Round size: Seed $1.6M–$10M; Pre-Seed $549k–$3.8M; Series A $9.7M–$47M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- EntryLevel — Learn in an affordable, peer-driven environment over 6 weeks with mentors from top companies across the world such as Atlassian, Wise and more.
- Sizable energy — Sizable Energy addresses the critical need for secure, affordable, and sustainable energy storage. Sizable Energy patented technology and straightforward design extends pumped hydro deployment to any offshore location with a depth of at least a few hundred meters. By leveraging a novel, modular, and easily deployable method, we utilize thegravitational potential of a solution 20% heavier than seawater, like saturated sea salt brine, within seawater.
- Koala Go — Your student's favorite online classroom. 24/7 live support. Co-browser. Gamified teaching environment. Worldwide invoicing. Interactive whiteboard.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Starfish Ventures is an Australian venture capital firm focused on information technology, life sciences, and clean technology companies.
Show more...Investment focus
- Industry: Software, Enterprise Software, Internet
- Stage:Series A, Series B
- Geography: Australia, United States, Philippines
Investor stats
- Total investments: 55
- Round size: Series A $2M–$6.6M; Series B $2.5M–$18M
- Lead/follow: 49% lead, 51% follow
- Last fund: May invest from a new fund soon — raised $134M in 2008
Portfolio highlights
- CAP-XX — CAP-XX develops, manufactures, and markets high power, high energy supercapacitors in thin, flat, prismatic packages.
- DesignCrowd — Crowdsourced logo, freelance graphic and web design at DesignCrowd. 1,328,201 freelance designers compete to create amazing designs for your business. Start Today!
- Smart Urban Properties Australia (SUPA) — Smart Urban Properties Australia (SUPA) offers a unique range of property solutions by bringing together renewable energy and mobility, super-speed fiber, and smart prop-tech. It is formed by bringing together Epsilon Security, b.energy, Fibrecorp, Smart Automation Systems, and connecX.
QIC BioVentures, previously known as Queensland BioCapital Funds, was established by the Queensland Investment Corporation (QIC) in October 2002 as its venture capital arm specialising in biotechnology. Like any other QIC Fund, QBF's purpose is to maximize investment returns for QIC's clients. QBF does not provide grants or other formsof assistance.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A
- Geography: Australia
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Verva Pharmaceuticals — Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined productportfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need.Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.
- Protagonist Therapeutics — Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.
The Clean Energy Finance Corporation invests using a commercial approach to overcome market barriers and mobilize investment in renewable energy, energy efficiency, and low emissions technologies. They seek to catalyze and leverage private sector funding for the commercialization and deployment of clean energy technologies necessary for thetransition to a carbon-constrained economy.
Show more...Investment focus
- Industry: Energy, Renewable Energy, Real Estate
- Stage:Debt Financing, Series B, Post-IPO Debt
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 126
- Round size: Series B $5M–$77M; Post-IPO Debt $42M–$719M; Debt Financing $18M–$329M
- Lead/follow: 42% lead, 58% follow
- Last fund: May invest from a new fund soon — raised $62M in 2018
Portfolio highlights
- FlexiGroup —
- Relectrify — Unlocking extra lifetime and performance of batteries via advanced battery management (BMS) technology.
- Quintessential Equity —
Investible is an early-stage venture capital firm backing the visionaries advancing humanity through technology in Australia, New Zealand, Southeast Asia and globally.
Show more...Investment focus
- Industry: Software, Information Technology, FinTech
- Stage:Seed, Series A, Pre-Seed
- Geography: Australia, United States, Singapore
Investor stats
- Total investments: 190
- Round size: Seed $250k–$5.1M; Pre-Seed $392k–$2M; Series A $1.4M–$20M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- fileAI — Automate and analyze any file with AI. fileAI builds proprietary AI components for complex agentic workflow automation.
- VoiceByte — VoiceByte is an application platform that allows its users to record and share their voice either privately or on social networks.
- GeoSnapShot — Let's put your photos to work. Built for professionals, available to everyone. GeoSnapShot is loved by amateurs, professionals, teams and individuals.
UniQuest is a university commercializing and technology transfer company.
Show more...Investment focus
- Industry: Biotechnology, Water, Medical
- Stage:Seed, Series A, Series B
- Geography: Australia, United Kingdom
Investor stats
- Total investments: 3
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- PERKii — PERKii Targeted Release Probiotics are naturally micro-shielded to resist stomach acid up to 10,000x stronger than non micro-shield probiotics. For a targeted release in your gut and a difference you can feel. PERKii Probiotic Drinks are bottled with one billion or more probiotics per serve.
- Vicebio — Discover Sanofi's commitment to scientific innovation, our R&D focus areas, product pipeline, and digital approach to transforming the practice of medicine.
- Earthodic — Earthodic is an Australian materials science company creating functional biobased coatings. Paperbarc by Earthodic is a biobased water-resistant coating for pulped or paper products. It has better water-resistance than wax coatings, more sustainable and circular than plastic coatings. Repulpable. Re
Empath Ventures is a venture capital firm that mainly invests in psychedelic medicine companies. The firm specializes in the fields of investment financial services, finance, and venture capital. It was founded in 2021 and headquartered in Los Angeles California.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Personal Health
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 17
- Round size: Seed $1.5M–$12M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Xylo Bio — Psylo is an Australia-based psychedelic biotech business focusing on Psychedelic-inspired medicine to treat mental illness.
- Motif Neurotech — We're building DOT, a miniature brain stimulator designed to restore healthy brain activity in patients with treatment-resistant depression.
- Aperture Therapeutics — Aperture Therapeutics is building an innovative drug discovery platform that embraces the genetic diversity of patients and leverages mechanistic understanding of protective gene variants in the human population.
The George Institute is on a mission to improve the health of millions of people worldwide. Join us in our fight for a healthier world.
Show more...Investment focus
- Industry: Biometrics, Health Care, Biotechnology
- Stage:Seed
- Geography: Australia
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- CellSync — CellSync is a Biotechnology Research firm that is working to make changes in the Future of Cell Engineering.
- Sineva — Sineva is a medical device manufacturing firm that makes ultrasonography simulators.
- Neogenix Biosciences — NeoGenix Fertility: Selecting sperm for life through microfluidics and AI
Lowercarbon Capital backs kickass companies slashing CO2 emissions, sucking carbon out of the sky, and buying us time to unf**k the planet.
Show more...Investment focus
- Industry: Renewable Energy, Energy, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 207
- Round size: Seed $3.7M–$12M; Series A $10M–$50M; Series B $20M–$150M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — raised $350M in 2022
Portfolio highlights
- Terraton — Terraton is a biochar platform that provides equipment, design, and financing to agribusiness operators.
- Isometric — Isometric is a carbon removal standard and registry.
- SolarSquare Energy — Visit Solarsquare, India's only UL-certified solar installation company for hassle-free commercial & residential solar panel installation at 0 cost EMI & PPA options.
The Global Health Investment Fund (GHIF) is a $108 million social impact investment fund designed to provide financing to advance the development of drugs, vaccines, diagnostics and other interventions against diseases that disproportionately burden low- and middle-income countries. GHIF supports late-stage innovations for public health challengessuch as malaria, pre-eclampsia, cholera, HIV and river blindness, with an emphasis on infectious diseases and maternal/infant health issues that cause significant morbidity and mortality in resource-limited settings. GHIF may also make investments that improve or expand access to existing products—such as developing pediatric formulations of approved therapeutics or improving the stability of widely-used global health vaccines.As an investment fund with a limited time-horizon, GHIF seeks opportunities that have a high probability of successful commercialization within two or three years. Products with “dual market” potential are of greatest interest; i.e., those that will have a clear impact on public health in developing countries but also have value in high-income countries. High-volume / low-margin products, such as essential vaccines, are also of significant interest.GHIF employs a range of investment structures including mezzanine debt, convertible debt, preferred equity and project financing with an average investment target of approximately $10 million per project. Each GHIF project must advance the Fund’s social impact objectives and demonstrate the ability to achieve commercial success.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series B, Series C
- Geography: United States, India, Austria
Investor stats
- Total investments: 18
- Round size: Series B $7.5M–$18M; Series C $4.5M–$14M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $108M in 2012
Portfolio highlights
- Monod Bio — Monod Bio l Simple. Powerful. Biosensors for Medicine & Biotech.
- CXL Ophthalmics — CXLO is developing a minimally invasive treatment for an ectatic corneal disease that can bring early intervention to millions of patients globally.
- Endpoint Health — Endpoint Health is a precision-first therapeutics company. By rewriting the molecule-first drug development model, we aim to deliver precision therapies that have the potential to improve outcomes for patients with immune-driven illnesses.
Vectr is a venture firm based in Hong Kong. They combine investment, creation and growth to deliver game-changing impact to teams ready to tackle global issues, transform industries and improve the lives of millions.That combines capital, creation and partnership to deliver game-changing impact. We strive to be the ideal partner for founders thatare building transformation products and looking to expand their businesses into asia.
Show more...Investment focus
- Industry: FinTech, Financial Services, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, Hong Kong, Singapore
Investor stats
- Total investments: 75
- Round size: Seed $547k–$5.3M; Series A $1M–$37M; Series B $12M–$70M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Percent — Unlock private credit investments with Percent. Access alternative investments on the platform powering the future of private markets.
- Micro Connect — Micro Connect provides market infrastructure, fintech, and platform development.
- MasterExchange — Trading platform for music rights leveraging emerging technology to create friction free and compliant investment opportunities to everyone.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Folklore is a team of investors, founders, and builders committed to supporting Australian and New Zealand tech founders. We are a first cheque to forever investment firm, and we believe in the power of founder vision and the potential of teams, right from the start.
Show more...Investment focus
- Industry: Software, Information Technology, Apps
- Stage:Seed, Series A
- Geography: Australia, United States, New Zealand
Investor stats
- Total investments: 47
- Round size: Seed $725k–$5M; Series A $500k–$21M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- Arkeus — Arkeus is a leader in the fusion of optics and autonomy. Our wide area autonomous optical systems are deployed to conduct Search, Intelligence, Surveillance and Reconnaissance in a range of operating environments.
- Hullbot — Hullbot is a developer of a robotic in-water cleaning system designed to inspect, map, and clean the hull of a boat without a human operator present. They offer design, development, and deployment of autonomous drones, delivering solutions to stop the growth of marine organisms, improve performance, and extend the time between haul-outs. Theirembedded intelligence enables their robots to interact with the environment on-the-fly.
- Sphere — Live courses led by vetted experts for professionals who want to advance their careers
Official website of Hitachi, Ltd. Hitachi drives Social Innovation Business, creating a sustainable society with data and technology. We will solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Series A, Series B, Series C
- Geography: United States, Australia, United Kingdom
Investor stats
- Total investments: 68
- Round size: Series A $10M–$50M; Series B $21M–$100M; Series C $30M–$200M
- Lead/follow: 21% lead, 79% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Arcee.ai — Learn how Arcee helps you build your own LLMs in your own cloud.
- ClearOps — ClearOps is a firm that provides B2B supply chain software for data-driven supply chain optimisation in the machine manufacturing industry.
- Exponent Energy — Simplifying Energy For EVs
The BridgeLane Group is a privately-owned asset management firm specialising in the agricultural, real estate and innovation sectors. A significant global player in agriculture with a multi-decade record in large scale farming, the Group has a proud history in residential property development, comme
Show more...Investment focus
- Industry: Software, Real Estate, Financial Services
- Stage:Seed, Series A
- Geography: Australia, Germany, United States
Investor stats
- Total investments: 20
- Round size: Seed $673k–$4.2M; Series A $3M–$6.1M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- MadeComfy — Award-winning Airbnb management service in Australia and New Zealand. MadeComfy is a selected official partner of Airbnb. Find out how we earn you higher returns with short-term rentals.
- Futurerent — Futurerent is a tool that offers solutions to residential property investors for investment capital and cashflow needs.
- Evrima Technologies — Our clinical trial recruitment and management services put participants first. Trusted, timely clinical trial results are a good thing - for everybody.
We Invest in the Circular Economy, a New Economic Model Focused on a Profitable and Sustainable Future.
Show more...Investment focus
- Industry: Recycling, Manufacturing, Artificial Intelligence
- Stage:Seed, Series A, Debt Financing
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 47
- Round size: Seed $2M–$7M; Series A $6M–$16M; Debt Financing $2.6M–$10M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — raised $200M in 2022
Portfolio highlights
- Supersede — Looking for sustainable lightweight waterproof plywood alternative. Upgrade your marine and construction projects with Supersede eco friendly materials.
- Evergreen — Evergreen, a division of Greenbridge, was originally established in 1998 to provide a sustainable, reliable supply of quality polyester resin for the company’s portfolio of PET strapping.
- Reterra — Save the environment with Reterra Corporation in Houston, TX. We recycle PET plastics into sustainable raw materials. Learn more on our site.
Join our leading Australian superannuation fund, committed to putting our members first, with a low admin fee and strong returns. Become a member today!
Show more...Investment focus
- Industry: Software, Biotechnology, Semiconductor
- Stage:Series A, Series B, Series C
- Geography: Australia, United Kingdom, United States
Investor stats
- Total investments: 62
- Round size: Series A $6.3M–$49M; Series B $20M–$111M; Series C $13M–$60M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Gradiant — Gradiant deploys advanced water treatment solutions and technologies to solve the toughest water challenges for the world's critical industries.
- First Light Fusion — First Light Fusion was spun out from the University of Oxford and focuses on researching energy generation by inertial confinement fusion. Its platform explores a number of alternative research directions that harness fundamental physics focusing on power generation and theoretical analysis, detailed numerical simulation, and experimentalvalidation that helps clients to discover a new source of energy. The company directly employs a team of engineers and physicists and collaborates closely with a number of academic organizations, including the University of Oxford, Warwick University, UCL, and Imperial College, London.The company was founded by Professor Yiannis Ventikos and Dr. Nicholas Hawker and is based in Yarnton, Oxfordshire.
- Gilmour Space Technologies — Gilmour Space is a rocket company in Australia that is developing and launching low-cost small satellite launch vehicles. All orbits, all planets: https://www.gspacetech.com
We are a global alternative asset manager creating sustainable value by partnering with ambitious businesses
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Private Equity, Series B
- Geography: United Kingdom, France, United States
Investor stats
- Total investments: 41
- Round size: Series B $50M–$172M; Private Equity $49M–$439M
- Lead/follow: 73% lead, 27% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- FUNECAP GROUPE — FUNECAP GROUPE provides activities and national services of funeral parlors, crematoriums, coffins, marble works, funerary articles, funeralROC ECLERC remains true to its policy: the guarantee of the best quality of services and products at prices accessible to all. The brand carries strong values of respect for families, irreproachable qualityand the search for the right price. They represent a constant commitment to families.
- Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.
- Excellera Advisory Group — Excellera Advisory Group is an Italian consultancy specializing in government affairs and reputation management.
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 673
- Round size: Series A $5M–$42M; Series B $8M–$75M; Series C $7.1M–$55M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — raised $100M in 2024
Portfolio highlights
- withco — withco is a provider of real estate and technology services for small businesses. withco was founded in 2019 and is based in Brooklyn, NY, USA.
- Berkshire Grey — Berkshire Grey develops a materials handling system intended to automate omnichannel fulfillment. Its system utilizes artificial intelligence, computer vision, machine learning, and novel sensing to deploy intelligent robotic systems that automate tasks never before performed by machines in commercial settings, enabling customers to achieve higheraccuracy and throughput speeds than traditional approaches as well as handle the broadest assortment of products, packaging, and parcels with ease.
- GroundWork — GroundWork delivers Unified Monitoring for Real™ with an open software platform for shockingly easy integrations and customized visualizations of cloud, virtualization, network, application, server, and storage data.GroundWork Monitor is available in free (Core) and subscription versions with support (Enterprise).GroundWork was founded in 2004 andis headquartered in San Francisco, California with partners in Asia Pacific, Europe and South America.
Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Management, an elite group of world-renowned, serial scientist-entrepreneurs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B
- Geography: United States, Switzerland, Israel
Investor stats
- Total investments: 129
- Round size: Series A $15M–$150M; Series B $26M–$150M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- OSPRI — Multiplex qPCR reagent kits for assay development, biomarker discovery, and translational research. 120+ configurations across a broad range of research areas. Extraction-free. Customizable. For Research Use Only.
- Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
- Medical Informatics — Medical Informatics offers solutions that give care teams access to the data they need to take action for alarm management and safety. The company’s Sickbay software platform enables continuous data collection from a comprehensive set of devices. Ultimately their alarm management solutions reduce alarm noise at the patient level, and send the rightalarms to care providers.Medical Informatics Corp was founded by Emma Fauss and Craig Rusin in 2010 and is based in Houston, Texas.
Great tech startup businesses are built by amazing product teams
Show more...Investment focus
- Industry: Health Care, SaaS, Medical
- Stage:Pre-Seed, Seed, Series A
- Geography: Australia, United States
Investor stats
- Total investments: 11
- Round size: Seed $2.9M–$8M; Pre-Seed $200k–$1M
- Lead/follow: 45% lead, 55% follow
Portfolio highlights
- Hola Health — 24 hour online doctors & GP consults via telehealth appointments in 15 minutes. Get instant scripts online, medical certificate online anywhere in Australia.
- Emanda — Emanda App helps business advisory firms and companies determine business value, auto-generate data rooms, set goals, and track progress daily via AI-driven tools.
- Flowing Bee — Revolutionise your customer interactions using AI, customer and behavioural insights. We create powerful marketing communications that drive behaviour change.
Tenacious Ventures - Australia's first and only dedicated agrifood tech VC firm.
Show more...Investment focus
- Industry: Agriculture, AgTech, Farming
- Stage:Seed, Pre-Seed, Series A
- Geography: Australia, United States
Investor stats
- Total investments: 24
- Round size: Seed $992k–$10M; Pre-Seed $896k–$2.2M; Series A $5.9M–$49M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Nbryo —
- Agovor —
- SwarmFarm Robotics — Global crop protection specialists ADAMA and Australian ag-tech company.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Radar Ventures operates as an venture capital firm.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Artificial Intelligence
- Stage:Seed, Pre-Seed, Series A
- Geography: Australia, United States, Hong Kong
Investor stats
- Total investments: 13
- Round size: Seed $1.9M–$12M
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- Acumino — Acumino offers next-generation, AI powered robot models for the execution of highly dexterous tasks in industrial automation settings. The Acumino AI is trained on the most accurate data of robot interactions and facilitates the deployment of next-generation intelligent robot workers in a fast, scalable, reliable, cost-efficient manner, unlockingunmatched dexterity & ROI.
- OncoRes Medical — OncoRes Medical develops an imaging technology to provide intraoperative information available to surgeons to assist with the identification of tumor and healthy tissue.OncoRes Medical is an early-stage medical device company located in Perth, Western Australia and is developing the patent-protected technology in collaboration with leadingresearchers at the University of Western Australia and the Harry Perkins Institute of Medical Research and breast cancer surgeons at the Western Australian public health system.With funding provided by the Medical Research Commercialisation Fund (MRCF), OncoRes Medical aims to develop the technology for use in clinical applications that require the real-time assessment of tissue microstructure.
- Diag-Nose.io — Antibiotic resistance is rising to dangerously high levels in all parts of the world threatening our ability to treat common infectious diseases. Diag-Nose is working on a novel diagnostic tool to non-invasively distinguish between viral,bacterial and allergy-mediated sinusitis.
Renew Pharmaceuticals is an healthcare company.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B
- Geography: Australia
Investor stats
- Total investments: 3
- Round size: Series A $5.6M–$6M
- Lead/follow: 67% lead, 33% follow
Portfolio highlights
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
South Australian Venture Capital Fund - helping build dynamic and innovative South Australian startups / scaleups and accelerate their growth to a national and global scale.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Internet of Things
- Stage:Seed, Series B, Series A
- Geography: Australia
Investor stats
- Total investments: 13
- Round size: Seed $1M–$12M; Series A $2.4M–$20M; Series B $13M–$24M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Seonix Bio — Seonix Bio is dedicated to helping health professionals, individuals and researchers understand glaucoma risk using genetics.
- Pearler.AI — Pearler gives your team super powers to respond fast to RFP, RFI, RFQ, Security, Cyber, Risk & Grant Questionnaires.
Queensland Investment Corporation is an investment company.
Show more...Investment focus
- Industry: Information Technology, Software, Renewable Energy
- Stage:Seed, Series A
- Geography: Australia, United States
Investor stats
- Total investments: 28
- Round size: Seed $673k–$10M; Series A $3.6M–$10M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $17M in 2022
Portfolio highlights
- Skedulo — Schedule and manage your deskless workforce, resolve conflicts, optimize travel, and more with our powerful scheduling app and mobile workforce management software.
- ModnPods —
- Pacific Energy — Our innovative energy solutions are transforming the way power is generated, delivered, and managed across the nation.
Monash University is an educational institution that offers undergraduate, graduate, and research courses in the fields of business, social sciences, science, and law. The schools of the university include Victorian College of Pharmacy, School of Nursing, and School of Applied Science.The university has a number of centers, five of which are inVictoria (Clayton, Caulfield, Berwick, Peninsula, and Parkville) and one in Malaysia. Monash also has a research and teaching center in Prato, Italy; a graduate research school in Mumbai, India; and a graduate school in Jiangsu Province, China.Monash University was founded in 1958 and is based in Melbourne, Australia.
Show more...Investment focus
- Industry: Biopharma, Therapeutics, Biotechnology
- Stage:Series A, Seed
- Geography: Australia
Investor stats
- Total investments: 3
- Round size: Series A $17M–$19M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- ElectraLith — The cleanest, most versatile and most cost-efficient method of extracting and refining lithium, the primary element of a sustainable future.
- Atisama Therapeutics — RAGE Biotech is a biotechnology industry.
- Inosi Therapeutics — Inosi Therapeutics develop therapies to address fibrosis.
Mike Wallas - Advisory Board @ Optifire Pty Ltd
Show more...Investment focus
- Industry: Video, Water, Biotechnology
- Stage:Seed
- Geography: Australia
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- PERKii — PERKii Targeted Release Probiotics are naturally micro-shielded to resist stomach acid up to 10,000x stronger than non micro-shield probiotics. For a targeted release in your gut and a difference you can feel. PERKii Probiotic Drinks are bottled with one billion or more probiotics per serve.
- Clipchamp — Create videos with royalty-free music and stock footage, use video templates, and export in up to 4K video resolution. Get started in-browser or download the Windows app.
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Therapeutics
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Australia
Investor stats
- Total investments: 194
- Round size: Seed $393k–$7.6M; Series A $2M–$23M
- Lead/follow: 21% lead, 79% follow
- Last fund: May invest from a new fund soon — raised $125M in 2014
Portfolio highlights
- Eight19 — Eight19, located in Cambridge, UK, develops and manufactures plastic photovoltaics for energy harvesting, for the internet of things and for off-grid applications. Through the innovative use of industry-standard, high-volume, roll-to-roll processes and solution-based organic photoactive materials, the company has a highly cost-effective route forscaling-up its technology to supply the largest markets. Eight19 is currently producing modules on a small scale for commercial partners with applications in indoor energy harvesting for wireless sensor and controllers, signage and display, and outdoor power for portable electronics. Our plastic PV modules benefit from flexibility, thinness, light-weight and robustness.
- Slamcore — Positioning, mapping and perception | State-of-the-art visual SLAM turns sensor data into actionable, spatial understanding for your vehicles.
- AudioScenic — THE NEW DIMENSION IN SOUND
Time Ventures is an investment fund for Marc Benioff. The company looks to invest in theB2B, hospitality, non-financial services, and commercial products and services sectors.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: United States, Canada, Germany
Investor stats
- Total investments: 50
- Round size: Seed $2.9M–$450M; Series A $11M–$80M; Series B $37M–$140M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Laurel — Time by Ping frees lawyers from timekeeping so they can focus on their work, and firms can understand where time is being spent.
- MoonPay — MoonPay offers a fast and simple way to buy and sell cryptocurrencies. Buy crypto with credit card, bank transfers or Apple Pay today.
- Regrow Ag — At Regrow, we empower farmers and partners to transform agriculture, build regenerative practices and combat climate change.
Allan Moss acts an adviser to Anchorage’s Investment Committee. Currently Principal of Allan Moss Investments, a private investment company, Allan retired from the role of Managing Director and Chief Executive Officer of Macquarie Group in May 2008. He was with Macquarie Group for 31 years and served as CEO from 1993 to his retirement in2008. He was also a non- executive director of CSR Ltd from 1996 to 2001.Allan graduated from Sydney University in Arts with a major in Economics and in Laws with Honours. He is also a graduate of Harvard University with a Masters Degree in Business Administration with High Distinction. Allan has received numerous industry awards and recognitions. He was twice named by Barron’s Magazine as one of the 30 most respected CEOs in the world (2006, 2007). He was appointed an Officer of the Order of Australia in 2005.
Show more...Investment focus
- Industry: Health Care, Medical Device, Biotechnology
- Stage:Series A, Seed
- Geography: Australia, United States, The Netherlands
Investor stats
- Total investments: 9
- Round size: Series A $2.4M–$8.8M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Skykraft — Skykraft is an Australian space services firm that specializes in smallsat constellation design, production, and operation.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Invert Robotics — Invert Robotics develops robotic NDT inspection technologies for the maintenance of industrial equipment in the food and beverage, pharmaceutical, and oil and gas industries. Invert Robotics highly skilled team of engineers have developed a world leading modular inspection platform suitable for use across a range of industries and applications.
Biotech Investor funding in Australia at a glance
Stats across 332 deals from 317 investors.
Access all 317 investors in Australia Biotech startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Investors in Australia investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 317 investors investing in Australia Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!